The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Abbvie; AstraZeneca; Janssen; Sunesis Pharmaceuticals
Speakers' Bureau - Janssen
Research Funding - Abbvie; Janssen
Fixed-duration (FD) first-line treatment (tx) with ibrutinib (I) plus venetoclax (V) for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of the FD cohort of the phase 2 captivate study.
 
Paolo Ghia
Honoraria - Abbvie; Acerta Pharma/AstraZeneca; Adaptive Biotechnologies; ArQule; BeiGene; Gilead Sciences; Janssen; Juno/Celgene; Loxo/Lilly; Sunesis Pharmaceuticals
Consulting or Advisory Role - Abbvie; Acerta Pharma/AstraZeneca; Adaptive Biotechnologies; ArQule; BeiGene; Gilead Sciences; Janssen; Juno/Celgene; Loxo/Lilly; Sunesis Pharmaceuticals
Research Funding - Abbvie; Gilead Sciences; Janssen; Novartis; Sunesis Pharmaceuticals
 
John N. Allan
Honoraria - Abbvie; AstraZeneca; BeiGene; Pharmacyclics/Janssen
Consulting or Advisory Role - Abbvie/Genentech; Ascentage Pharma; AstraZeneca; BeiGene; Epizyme; Janssen Oncology; Pharmacyclics
Research Funding - Celgene; Genentech; Janssen; TG Therapeutics
 
Tanya Siddiqi
Consulting or Advisory Role - AstraZeneca; BeiGene; Celgene; Juno therapeutics; Kite, a Gilead company
Speakers' Bureau - AstraZeneca; Janssen; Pharmacyclics
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Celgene (Inst); Juno Therapeutics (Inst); Kite, a Gilead company (Inst); Oncternal Therapeutics (Inst); Pharmacyclics (Inst); TG therapeutics (Inst)
 
Thomas J. Kipps
Employment - Moores Cancer Center
Stock and Other Ownership Interests - Oncternal Therapeutics, Inc
Honoraria - Abbvie; AstraZeneca; Dava Oncology; Genentech; Gilead Sciences; Janssen; Pharmacyclics
Consulting or Advisory Role - Abbvie; Dava Oncology; Genentech; Janssen; Pharmacyclics
Speakers' Bureau - Abbvie/Genentech; DAVA Pharmaceuticals; Gilead Sciences; Pharmacyclics/Janssen; Verastem/Pharmacyclics
Research Funding - Breast Cancer Research Foundation (Inst); California Institute for Regenerative Medicine (CIRM) (Inst); Leukemia and Lymphoma Society (Inst); National Cancer Institute (Inst); NIH (Inst); Oncternal Therapeutics, Inc (Inst); Pharmacyclics/Janssen (Inst)
Patents, Royalties, Other Intellectual Property - Cirmtuzumab was developed by Thomas J. Kipps in the Thomas J. Kipps laboratory and licensed by the University of California to Oncternal Therapeutics, Inc., which provided stock options and research funding to the Thomas J. Kipps laboratory. (Inst)
Travel, Accommodations, Expenses - Abbvie/Pharmacyclics; AstraZeneca; Breast Cancer Research Foundation; Celgene; Dava Oncology; Genentech/Roche; Gilead Sciences; Janssen; TG Therapeutics; Verastem
 
Ryan Jacobs
Consulting or Advisory Role - Abbvie; AstraZeneca; Pharmacyclics; Verastem
Speakers' Bureau - Abbvie; AstraZeneca; Genentech; Janssen; Pharmacyclics; Sanofi
Research Funding - Pharmacyclics; TG Therapeutics
 
Stephen Opat
Honoraria - Abbvie; AstraZeneca; CSL Behring; Gilead Sciences; Janssen; Merck; Mundipharma; Roche; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Celgene; CSL Behring; Gilead Sciences; Janssen; Merck; Mundipharma; Novartis; Takeda
Research Funding - Abbvie (Inst); AstraZeneca (Inst); BeiGene (Inst); Celgene (Inst); Epizyme (Inst); Gilead Sciences (Inst); Janssen (Inst); Merck (Inst); Pharmacyclics (Inst); Roche (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Roche
 
Paul M. Barr
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb/Celgene; Genentech; Infinity Pharmaceuticals; Janssen; MEI Pharma; Merck; MorphoSys; Novartis; Pharmacyclics; Seagen; TG Therapeutics
Research Funding - AstraZeneca (Inst); Pharmacyclics (Inst)
 
Alessandra Tedeschi
Consulting or Advisory Role - Abbvie; AstraZeneca; BeiGene; Janssen; Sunesis Pharmaceuticals
Speakers' Bureau - Abbvie; Janssen
 
Livio Trentin
Consulting or Advisory Role - Abbvie; Janssen; Octapharm
Research Funding - Janssen Scientific Affairs (Inst)
 
Rajat Bannerji
Employment - Sanofi Pasteur (I)
Research Funding - Abbvie (Inst); Abbvie/Pharmacyclics (Inst); Genentech (Inst); Regeneron (Inst); Roche (Inst)
 
Sharon Jackson
Consulting or Advisory Role - Abbvie
Travel, Accommodations, Expenses - Roche
 
Byrone Kuss
Stock and Other Ownership Interests - Commonwealth Serum Laboratories (CSL)
Honoraria - Abbvie; Janssen; Kyowa Kirin; Merck; Mundipharma; Roche; Takeda
Consulting or Advisory Role - Abbvie; Janssen; Kyowa Kirin; Merck; Mundipharma; Roche; Takeda
Speakers' Bureau - Abbvie; Janssen; Roche
Expert Testimony - Abbvie
 
Carol Moreno
No Relationships to Disclose
 
Edith Szafer-Glusman
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Kristin Russell
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Cathy Zhou
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Joi Suzuki Ninomoto
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie; Amgen; Celgene
 
James P. Dean
Employment - Pharmacyclics
Stock and Other Ownership Interests - Abbvie
 
William G. Wierda
Consulting or Advisory Role - Sanofi
Research Funding - Abbvie; Acerta Pharma; Cyclacel; Emergent BioSolutions; Genentech; Gilead Sciences; GlaxoSmithKline/Novartis; Janssen; Juno Therapeutics; Karyopharm Therapeutics; Kite, a Gilead company; Loxo; miRagen; Oncternal Therapeutics, Inc; Pharmacyclics; Sunesis Pharmaceuticals; Xencor
 
Constantine Si Lun Tam
Honoraria - Abbvie; Beigene; Janssen-Cilag; Novartis; Pharmacyclics
Consulting or Advisory Role - Abbvie; BeiGene; Janssen; Loxo; Roche
Research Funding - Abbvie (Inst); Janssen-Cilag (Inst)